Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CBAY Stock Summary
Top 10 Correlated ETFs
CBAY
In the News
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.
Why is CymaBay (CBAY) Stock Up 25% Today?
CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.
Gilead to buy CymaBay Therapeutics for $4.3 billion
CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
Gilead strikes deal to acquire CymaBay for $4.3 billion
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.
CymaBay Therapeutics to Present at Upcoming Investment Conferences
NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9t h in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update.
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CBAY Financial details
CBAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.29 | |
Net income per share | -1.53 | -0.71 | -1.31 | -1.36 | -0.99 | |
Operating cash flow per share | -1.46 | -0.65 | -0.98 | -0.96 | -0.68 | |
Free cash flow per share | -1.47 | -0.65 | -0.98 | -0.96 | -0.69 | |
Cash per share | 2.85 | 2.12 | 2.63 | 1.55 | 3.71 | |
Book value per share | 2.78 | 2.07 | 1.88 | 0.41 | 2.75 | |
Tangible book value per share | 2.78 | 2.07 | 1.88 | 0.41 | 2.75 | |
Share holders equity per share | 2.78 | 2.07 | 1.88 | 0.41 | 2.75 | |
Interest debt per share | 0.03 | 0.03 | 0.76 | 1.21 | 1.21 | |
Market cap | 131.38M | 395.45M | 239.52M | 549.28M | 2.51B | |
Enterprise value | 108.67M | 369M | 165.3M | 619.91M | 2.42B | |
P/E ratio | -1.29 | -8.13 | -2.59 | -4.62 | -23.81 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 80.73 | |
POCF ratio | -1.34 | -8.84 | -3.45 | -6.53 | -34.59 | |
PFCF ratio | -1.34 | -8.84 | -3.45 | -6.52 | -34.37 | |
P/B Ratio | 0.71 | 2.77 | 1.8 | 15.19 | 8.58 | |
PTB ratio | 0.71 | 2.77 | 1.8 | 15.19 | 8.58 | |
EV to sales | 0 | 0 | 0 | 0 | 77.77 | |
Enterprise value over EBITDA | -1.11 | -6.91 | -1.91 | -6.81 | -23.93 | |
EV to operating cash flow | -1.11 | -8.25 | -2.38 | -7.37 | -33.32 | |
EV to free cash flow | -1.11 | -8.25 | -2.38 | -7.36 | -33.11 | |
Earnings yield | -0.78 | -0.12 | -0.39 | -0.22 | -0.04 | |
Free cash flow yield | -0.75 | -0.11 | -0.29 | -0.15 | -0.03 | |
Debt to equity | 0.01 | 0.01 | 0.39 | 2.51 | 0.37 | |
Debt to assets | 0.01 | 0.01 | 0.25 | 0.64 | 0.25 | |
Net debt to EBITDA | 0.23 | 0.5 | 0.86 | -0.78 | 0.91 | |
Current ratio | 11.51 | 15.38 | 10.41 | 8.94 | 10.96 | |
Interest coverage | 0 | 0 | -33.91 | -6.25 | -5.37 | |
Income quality | 0.95 | 0.88 | 0.77 | 0.79 | 0.69 | |
Dividend Yield | 0 | 0 | 0 | 0.05 | 0 | |
Payout ratio | 0 | 0 | 0 | -0.21 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 1.67 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 2.58 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | -0.55 | -0.03 | -0.13 | -0.21 | -0.65 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.49 | |
Graham number | 9.77 | 5.74 | 7.43 | 3.55 | 7.84 | |
ROIC | -0.56 | -0.34 | -0.48 | -0.82 | -0.25 | |
Return on tangible assets | -0.5 | -0.32 | -0.46 | -0.84 | -0.24 | |
Graham Net | 2.57 | 1.97 | 1.65 | 0.34 | 2.37 | |
Working capital | 185.29M | 141.73M | 172.73M | 122.63M | 366.96M | |
Tangible asset value | 186.35M | 142.71M | 132.94M | 36.15M | 292.26M | |
Net current asset value | 183.54M | 140.47M | 121.72M | 32.38M | 261.37M | |
Invested capital | 0.01 | 0.01 | 0.39 | 2.51 | 0.37 | |
Average receivables | 343.5K | 482K | 138.5K | 0 | 0 | |
Average payables | 2.24M | 1.37M | 1.48M | 1.91M | 2.46M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.14K | 133.41 | 1.45K | 563.44 | 2.05K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.32 | 2.74 | 0.25 | 0.65 | 0.18 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.55 | -0.34 | -0.7 | -3.29 | -0.36 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.32 | 0 | 0 | |
Net income per share | -0.42 | -0.36 | -0.01 | -0.34 | -0.37 | |
Operating cash flow per share | -0.22 | 0.07 | -0.26 | -0.26 | -0.24 | |
Free cash flow per share | -0.22 | 0.06 | -0.26 | -0.26 | -0.24 | |
Cash per share | 1.56 | 2.41 | 2.19 | 4.35 | 3.48 | |
Book value per share | 0.42 | 1.06 | 1.11 | 3.23 | 2.58 | |
Tangible book value per share | 0.42 | 1.06 | 1.11 | 3.23 | 2.58 | |
Share holders equity per share | 0.42 | 1.06 | 1.11 | 3.23 | 2.58 | |
Interest debt per share | 1.09 | 1.02 | 1.07 | 0.99 | 1.01 | |
Market cap | 545.59M | 854.31M | 1.07B | 1.51B | 2.68B | |
Enterprise value | 616.22M | 890.32M | 1.13B | 1.34B | 2.58B | |
P/E ratio | -3.75 | -6.09 | -330.38 | -11.11 | -15.97 | |
Price to sales ratio | 0 | 0 | 34.43 | 0 | 46.96K | |
POCF ratio | -29.09 | 132.84 | -41.98 | -57.58 | -97.76 | |
PFCF ratio | -29.07 | 137 | -41.86 | -57.58 | -97.12 | |
P/B Ratio | 15.09 | 8.2 | 9.85 | 4.62 | 9.16 | |
PTB ratio | 15.09 | 8.2 | 9.85 | 4.62 | 9.16 | |
EV to sales | 0 | 0 | 36.49 | 0 | 45.34K | |
Enterprise value over EBITDA | -27.32 | -36.83 | 281.5 | -41.48 | -60.9 | |
EV to operating cash flow | -32.85 | 138.44 | -44.5 | -51.1 | -94.4 | |
EV to free cash flow | -32.83 | 142.77 | -44.38 | -51.1 | -93.78 | |
Earnings yield | -0.07 | -0.04 | 0 | -0.02 | -0.02 | |
Free cash flow yield | -0.03 | 0.01 | -0.02 | -0.02 | -0.01 | |
Debt to equity | 2.51 | 0.91 | 0.92 | 0.32 | 0.37 | |
Debt to assets | 0.64 | 0.39 | 0.44 | 0.23 | 0.25 | |
Net debt to EBITDA | -3.13 | -1.49 | 15.95 | 5.26 | 2.17 | |
Current ratio | 8.94 | 5.22 | 12.52 | 22.76 | 10.96 | |
Interest coverage | -5.76 | -6.1 | -0.02 | 6.65 | -8.36 | |
Income quality | 0.7 | -0.22 | 31.48 | 0.77 | 0.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.37 | 0 | 347.47 | |
Research and developement to revenue | 0 | 0 | 0.63 | 0 | 398.12 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | -0.03 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | -3.16 | |
Capex to depreciation | -0.07 | -0.98 | -0.33 | 0 | -3.21 | |
Stock based compensation to revenue | 0 | 0 | 0.11 | 0 | 81.91 | |
Graham number | 1.98 | 2.93 | 0.46 | 4.94 | 4.63 | |
ROIC | -0.25 | -0.16 | 0 | -0.07 | -0.1 | |
Return on tangible assets | -0.26 | -0.14 | 0 | -0.08 | -0.1 | |
Graham Net | 0.34 | 0.97 | 0.98 | 3.11 | 2.22 | |
Working capital | 122.63M | 196.22M | 206.18M | 427.99M | 366.96M | |
Tangible asset value | 36.15M | 104.19M | 108.41M | 326.19M | 292.26M | |
Net current asset value | 32.38M | 101.59M | 105.83M | 322.8M | 261.37M | |
Invested capital | 2.51 | 0.91 | 0.92 | 0.32 | 0.37 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 787.5K | 1.36M | 3.11M | 3.66M | 3.28M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 533.19 | 738.54 | 1.96K | 1.14K | 6.15K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.17 | 0.12 | 0.05 | 0.08 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.01 | -0.34 | -0.01 | -0.1 | -0.14 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CBAY Frequently Asked Questions
What is CymaBay Therapeutics, Inc. stock symbol ?
CymaBay Therapeutics, Inc. is a US stock , located in Newark of Ca and trading under the symbol CBAY
What is CymaBay Therapeutics, Inc. stock quote today ?
CymaBay Therapeutics, Inc. stock price is $32.48 today.
Is CymaBay Therapeutics, Inc. stock public?
Yes, CymaBay Therapeutics, Inc. is a publicly traded company.